Major findings supporting the involvement of CB2R in depressive disorders
| Animal studies | ||||||
|---|---|---|---|---|---|---|
| Genetic studies | Genetic manipulation | Animal specie | Experimental test | Behavioral changes | References | |
| CB2xP | Mouse, ICR | TST | ↓ immobility time | [39] | ||
| NSFT | ↓ latency time and ↑ food (g) consumption | [39] | ||||
| CMS | ↑ resistance(↑ sucrose 1% consumption and ↓ immobility time in TST) | [39] | ||||
| CB2–/– | Mouse, ICR | TST | ↑ immobility time | [44] | ||
| DAT-Cnr2–/– | Mouse, C57BL/6J | TST, FST | ↑ immobility time | [69] | ||
| Pharmacological studies | Drug | Animal specie | Experimental test | Dosis | Behavioral changes | References |
| AM630 (CB2R antagonist) | Mouse, ICR | CMS | 1 mg/kg per 12 h (4 weeks) | Antidepressive actions (↑ immobility time in TST and ↑ sucrose 1% consumption) | [39] | |
| Mouse, BALB/c C57BL/6J | CMS | 3 mg/kg per 24 h (4 weeks) | No effect | [45] | ||
| Human studies | |||
|---|---|---|---|
| Variable | Population | Results | References |
| Q63R polymorphism | Japanese | ↑ incidence | [45] |
| CB2R expression | Caucasian | ↓ in DLPFC and amygdala | [56] |
TST: tail suspension test; NSFT: novelty suppressed feeding test; FST: forced swimming test; CMS: chronic mild stress